Immunome (IMNM) director sells 65,000 shares in open market

Rhea-AI Filing Summary

Immunome Inc. director Philip Wagenheim sold shares of Common Stock in two open-market transactions. He sold 36,800 shares on March 20, 2026 at a weighted average price of $20.47 per share and 28,200 shares on March 23, 2026 at a weighted average price of $20.65 per share. After these sales, he directly owns 341,147 shares of Immunome Common Stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WAGENHEIM PHILIP

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		S		36,800	D	$20.47(1)	369,347	D
Common Stock	03/23/2026		S		28,200	D	$20.65(2)	341,147	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The weighted average sale price for the transaction report was $20.47, and the range of prices were between $20.07 and $20.96, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

2. The weighted average sale price for the transaction report was $20.65, and the range of prices were between $20.15 and $20.84, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Sandra Stoneman, Attorney-in-Fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunome (IMNM) director Philip Wagenheim report in this Form 4?

He reported selling 65,000 shares of Immunome Common Stock in open-market transactions. The sales occurred over two days and were executed at weighted average prices around $20.47 and $20.65 per share, according to the filing details and footnotes.

How many Immunome (IMNM) shares did the director sell and at what prices?

Philip Wagenheim sold 36,800 shares at a weighted average price of $20.47 and 28,200 shares at a weighted average price of $20.65. Footnotes note price ranges between $20.07–$20.96 and $20.15–$20.84, respectively.

When did the Immunome (IMNM) insider stock sales take place?

The reported sales took place on March 20, 2026 and March 23, 2026. Both transactions involved open-market sales of Immunome Common Stock, as indicated by transaction code S and the description of sale in open market or private transactions.

How many Immunome (IMNM) shares does the director hold after these transactions?

After completing the reported sales, Philip Wagenheim directly owns 341,147 shares of Immunome Common Stock. This post-transaction holding reflects his remaining direct ownership as shown in the Form 4 for the March 23, 2026 transaction entry.

Were the Immunome (IMNM) insider sales single-price or multiple-price trades?

They were reported as multiple-price trades. Footnotes state weighted average sale prices of $20.47 and $20.65 with price ranges for each day, and offer to provide full per-price breakdowns upon request to the SEC staff, issuer, or any security holder.

Do the Immunome (IMNM) Form 4 footnotes mention any special trading arrangements?

The footnotes describe weighted average sale prices and the price ranges for each transaction date, and offer to supply detailed per-price data upon request. They do not reference Rule 10b5-1 trading plans or other special trading arrangements in the provided excerpt.